This agonist combination has been demonstrated to be better than either agonist individually to activate conventional dendritic cells type 1 (cDC1) crucial for CD8+ T-cell cross-priming, and to increase tumor-antigen reactive CD8+ T-cells [[25], [26], [27]]. The gene discussed is CD8A; the disease is neoplasm.